title: Bioequivalence of a new strength tacrolimus capsule under development.
authors.affiliation: Department of Experimental Therapeutics, Fujisawa USA, Inc, Deerfield 60015, USA.
authors.forename: I
authors.initials: I
authors.lastname: Bekersky
authors.forename: D
authors.initials: D
authors.lastname: Dressler
authors.forename: G W
authors.initials: GW
authors.lastname: Boswell
authors.forename: B
authors.initials: B
authors.lastname: Fergen
authors.forename: W
authors.initials: W
authors.lastname: Tracewell
authors.forename: Q
authors.initials: Q
authors.lastname: Mekki
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002214:Capsules; D003198:Computer Simulation; D016001:Confidence Intervals; D018592:Cross-Over Studies; D005006:Ethnicity; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D008657:Metabolic Clearance Rate; D044469:Racial Groups; D011897:Random Allocation; D016559:Tacrolimus / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency
chemical_list: D002214:Capsules; D007166:Immunosuppressive Agents; D016559:Tacrolimus